Oculis announced the full randomization of its registrational dry eye trial for Licaminlimab, with 176 patients enrolled, two-thirds carrying a target genetic variant. Topline results are expected around year-end 2026, marking a significant milestone for this precision medicine approach in a large market.
Oculis has fully randomized its first genotype-guided registrational trial for Licaminlimab, a precision medicine for dry eye disease. This is a crucial step in the drug development process, as it confirms the trial is on track and provides a timeline for key data release. The high proportion of patients with the target TNFR1 genetic variant (two-thirds) suggests a strong focus on validating the precision medicine approach, which could lead to a more effective treatment for a specific patient population. For traders, this news reduces uncertainty around trial enrollment and sets a clear expectation for future catalysts (topline data YE2026). The long-term implication is the potential for Oculis to capture a significant share of the DED market if Licaminlimab proves successful, especially given the estimated 1.5+ million patients in the U.S. with TNFR1-mediated DED. The key opportunity is the potential for a first-in-class precision medicine in a large, underserved market.